Doronzo Gabriella, Russo Isabella, Mattiello Luigi, Trovati Mariella, Anfossi Giovanni
Diabetes Unit, Department of Clinical and Biological Sciences of the University of Turin, San Luigi Gonzaga Hospital, Orbassano (Turin), Italy.
Thromb Haemost. 2005 Dec;94(6):1285-93. doi: 10.1160/TH05-04-0221.
In this study we aimed to test the hypothesis that in human vascular smooth muscle cells (VSMC) homocysteine influences synthesis and release of matrix metalloproteinase-2 (MMP-2), which is deeply involved in vascular remodeling and atherosclerotic plaque instabilization. Experiments were carried out in cultured human VSMC exposed to 50-500 micromol/l homocysteine after a 24-hour culture with MEM containing 0.1% BSA. Both in supernatants and cell lysates we evaluated MMP-2 activity (gelatin zimography), MMP-2 andTIMP-2 protein synthesis (Western immunoblotting). Homocysteine effects were investigated also after cell exposure to i) specific MEK inhibitor PD98059 (30 micromol/l) to evaluate the involvement of Mitogen-Activated Protein Kinase (MAPK) and ii) specific phosphatidylinositol 3-kinase (P13-K) inhibitor LY294002 (100 micromol/l) to evaluate the involvement of P13-K pathway. Gelatin zimography evidenced that MMP-2 activity is increased both in conditioned media and in cell lysates starting from 8-hour incubation with 100 micromol/l homocysteine. Western blot analysis evidenced increased MMP-2 levels in both conditioned media and cell lysates. Cell exposure to PD98059 and LY294002 prevented homocysteine effects on MMP-2 synthesis. Homocysteine, at concentrations associated with increased risk of cardiovascular events, increases MMP-2 activity, synthesis and secretion in VSMC through a mechanism involving the activation of MAPK and P13-K pathways. These data suggest that homocysteine is directly involved in mechanisms leading to remodelling and instabilization of atherosclerotic plaques.
在本研究中,我们旨在验证以下假设:在人类血管平滑肌细胞(VSMC)中,同型半胱氨酸会影响基质金属蛋白酶-2(MMP-2)的合成与释放,而MMP-2与血管重塑和动脉粥样硬化斑块不稳定密切相关。实验在含有0.1%牛血清白蛋白(BSA)的MEM培养基中培养24小时后,用50 - 500微摩尔/升同型半胱氨酸处理培养的人类VSMC。我们在细胞培养上清液和细胞裂解物中评估了MMP-2活性(明胶酶谱法)、MMP-2和组织金属蛋白酶抑制因子-2(TIMP-2)的蛋白质合成(Western免疫印迹法)。在细胞分别暴露于以下物质后,研究了同型半胱氨酸的作用:i)特异性MEK抑制剂PD98059(30微摩尔/升),以评估丝裂原活化蛋白激酶(MAPK)的参与情况;ii)特异性磷脂酰肌醇3激酶(PI3-K)抑制剂LY294002(100微摩尔/升),以评估PI3-K途径的参与情况。明胶酶谱法证明,从用100微摩尔/升同型半胱氨酸孵育8小时起,条件培养基和细胞裂解物中的MMP-2活性均增加。Western印迹分析证明,条件培养基和细胞裂解物中的MMP-2水平均升高。细胞暴露于PD98059和LY294002可阻止同型半胱氨酸对MMP-2合成的影响。在与心血管事件风险增加相关的浓度下,同型半胱氨酸通过涉及MAPK和PI3-K途径激活的机制,增加VSMC中MMP-2的活性、合成和分泌。这些数据表明,同型半胱氨酸直接参与导致动脉粥样硬化斑块重塑和不稳定的机制。